PTGX stock news

PTGX stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-23 12:09:39 UTC#506491newconfirmednews

UK MHRA approves Johnson & Johnson and Protagonist Therapeutics' oral psoriasis pill Icotyde

reutersimportance 0.50trust 0.90Johnson & Johnson +0.40Medicines and Healthcare products Regulatory Agency +0.30Icotyde +0.50+2 entities

2026-10-21 15:07:14 UTC#493983newconfirmednews

TD Cowen maintains Buy rating on Protagonist Therapeutics, sets $160 price target

tradingviewimportance 0.30trust 0.60TD Cowen 0Protagonist Therapeutics, Inc. +0.40rusfertide +0.20+1 entities

2026-10-12 18:31:02 UTC#448321newconfirmednews

Leerink Partners names Nektar Therapeutics, Protagonist Therapeutics, and Shattuck Labs as top picks in immunology

seeking alphaimportance 0.40trust 0.60Nektar Therapeutics +0.40Protagonist Therapeutics, Inc. +0.40Shattuck Labs, Inc. +0.40+1 entities

2026-10-12 13:57:00 UTC#447026newconfirmednews

UBS initiates Protagonist Therapeutics (PTGX) at Buy with $184 price target

dow_jonesimportance 0.30trust 0.70Protagonist Therapeutics, Inc. +0.40UBS Group AG +0.40

2026-09-25 09:30:00 UTC#367652newconfirmedanalysis

Protagonist Therapeutics' oral peptide platform gains traction, challenging AbbVie's market position

dow_jonesimportance 0.40trust 0.80Protagonist Therapeutics, Inc. +0.60Johnson & Johnson +0.40AbbVie Inc. -0.30+1 entities

2026-09-10 16:00:50 UTC#293524duplicateconfirmednews

Protagonist Therapeutics (PTGX) confirms $300M share buyback and R&D expansion following drug approvals

quartrimportance 0.30trust 0.50Protagonist Therapeutics, Inc. +0.60

2026-09-10 15:16:15 UTC#293267newconfirmednews

Protagonist Therapeutics (PTGX) announces $300M share buyback following recent drug approvals

quartrimportance 0.40trust 0.60Protagonist Therapeutics, Inc. +0.60

2026-09-08 20:16:48 UTC#283387newconfirmednews

Protagonist Therapeutics authorizes $300 million share repurchase program

seeking alphaimportance 0.50trust 0.70Protagonist Therapeutics, Inc. +0.50

2026-09-07 11:22:09 UTC#276030duplicateconfirmednews

Protagonist Therapeutics MIMRYLO FDA approval and analyst price target hikes recap

tradingviewimportance 0.30trust 0.70Protagonist Therapeutics, Inc. +0.80Takeda Pharmaceutical Company Limited +0.50MIMRYLO +0.80+2 entities

2026-09-01 18:54:00 UTC#251521newconfirmednews

Barclays raises Protagonist Therapeutics (PTGX) price target to $180.00 from $153.00

dow_jonesimportance 0.40trust 0.70Protagonist Therapeutics, Inc. +0.40Barclays PLC +0.40

2026-08-31 16:09:01 UTC#243834duplicateconfirmednews

FDA approves Protagonist Therapeutics' MIMRYLO for polycythemia vera erythrocytosis

quartrimportance 0.30trust 0.60Protagonist Therapeutics, Inc. +0.80MIMRYLO +0.80Takeda Pharmaceutical Company Limited +0.60+1 entities

2026-08-31 14:53:00 UTC#243425newconfirmednews

H.C. Wainwright & Co. maintains Buy rating on Protagonist Therapeutics (PTGX)

dow_jonesimportance 0.30trust 0.70Protagonist Therapeutics, Inc. +0.20H.C. Wainwright & Co., LLC +0.20

2026-08-31 07:52:29 UTC#241253newconfirmednews

FDA approves Protagonist Therapeutics' MIMRYLO for polycythemia vera treatment

quartrimportance 0.70trust 0.70Protagonist Therapeutics, Inc. +0.80MIMRYLO +0.80Food and Drug Administration +0.50

2026-08-31 03:59:35 UTC#240611newconfirmednews

Jefferies raises Protagonist Therapeutics price target to $171 from $169

first_squawkimportance 0.30trust 0.70Jefferies Financial Group Inc. 0Protagonist Therapeutics, Inc. +0.30

2026-08-28 21:49:53 UTC#237510duplicateconfirmednews

FDA approves Takeda and Protagonist Therapeutics' Mimrylo for polycythemia vera

reutersimportance 0.50trust 0.90Takeda Pharmaceutical Company Limited +0.50Protagonist Therapeutics, Inc. +0.50U.S. Food and Drug Administration 0+2 entities

2026-08-28 21:37:44 UTC#237468newconfirmednews

FDA approves Takeda and Protagonist Therapeutics' new drug for rare blood cancer

reutersimportance 0.50trust 0.90Takeda Pharmaceutical Company Limited +0.50Protagonist Therapeutics, Inc. +0.60U.S. Food and Drug Administration +0.20

2026-08-28 18:53:53 UTC#236868duplicateconfirmednews

Johnson & Johnson and Protagonist receive China approval for oral psoriasis drug

seeking alphaimportance 0.30trust 0.70Johnson & Johnson +0.40Protagonist Therapeutics, Inc. +0.40China 0

2026-08-24 14:38:00 UTC#212820newconfirmedanalysis

Johnson & Johnson Pipeline Update: Recent Approvals for Inlexzo, Imaavy, and Icotyde Bolster Growth Outlook

yahooimportance 0.40trust 0.60Johnson & Johnson +0.40Protagonist Therapeutics, Inc. +0.30Inlexzo +0.40+2 entities

2026-08-17 13:00:00 UTC#184773newconfirmednews

BMO Capital maintains Outperform on Protagonist Therapeutics (PTGX), raises price target to $178 from $112

dow_jonesimportance 0.40trust 0.70Protagonist Therapeutics, Inc. +0.60BMO Capital Markets Corp. +0.60

2026-08-10 18:28:00 UTC#154313newconfirmednews

Truist Securities raises Protagonist Therapeutics (PTGX) price target to $170 from $145

dow_jonesimportance 0.30trust 0.70Protagonist Therapeutics, Inc. +0.40Truist Securities, Inc. +0.40